Gadolinium Lawyers Await Final Bellwether Trial Outcome
The fourth and final bellwether trial that will settle several gadolinium lawsuits has every gadolinium lawyer interested and awaiting the court’s decision. The bellwether trial, scheduled to commence October 31, 2011, has been allotted two weeks, excluding other processes and motions, such as opening statements, jury deliberations, voir dire, and closing arguments. A voir dire, in legal terms, is the… Read more »
Gadolinium Lawsuit News: Fourth Bellwether Trial Scheduled for End of October
Gadolinium lawyers will be watching closely as the fourth and final Gadolinium bellwether trial is scheduled for next week. With a court date of October 31, no word has yet been heard on whether there will be a pre-trial settlement like there was in the three previous bellwether trials. According to the most recent Gadolinium lawsuit news, this bellwether trial is… Read more »
Gadolinium Lawsuit Addresses Unusual Side Effects
Plaintiffs generally seek Gadolinium settlements on the grounds that they experienced a common Gadolinium effect such as nephrogenic systemic fibrosis (NSF). However, the plaintiff in a new Gadolinium lawsuit is seeking a settlement related to heart-based Gadolinium side effects. Nov. 19, 2010, Charles A. Bernardo, Sr. filed a lawsuit in the U.S. District Court, Middle District of Florida alleging that… Read more »
Gadolinium MDL in Ohio Continues to Grow
The gadolinium NSF lawsuit of plaintiff Edward Black is the latest to be filed in federal court by a gadolinium lawyer and subsequently transferred, on September 16, 2011, to the U.S. District Court for the Northern District of Ohio. Black alleges in his official complaint that he developed gadolinium nephrogenic systemic fibrosis after being injected with gadolinium-based contrast agents (GBCAs)… Read more »
Some Gadolinium-Based Agents More Toxic Than Others?
The FDA has approved seven brands of gadolinium-based contrast agents (GBCAs) for use in magnetic resonance imaging tests (MRIs). Though it’s not yet clear which may present more of a risk for gadolinium nephrogenic systemic fibrosis (NFS)—a serious and incurable health disorder—early scientific studies have implied that some may be more risky than others. Omniscan targeted in early gadolinium lawsuits… Read more »
